Indiana Trust & Investment Management CO raised its holdings in shares of Eli Lilly and Co (NYSE:LLY) by 7.5% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 10,857 shares of the company’s stock after purchasing an additional 760 shares during the period. Indiana Trust & Investment Management CO’s holdings in Eli Lilly and were worth $917,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. boosted its stake in Eli Lilly and by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 70,207,891 shares of the company’s stock worth $5,778,109,000 after purchasing an additional 1,610,885 shares in the last quarter. BlackRock Inc. boosted its stake in Eli Lilly and by 2.1% in the 2nd quarter. BlackRock Inc. now owns 63,583,747 shares of the company’s stock worth $5,232,942,000 after purchasing an additional 1,323,259 shares in the last quarter. Janus Henderson Group PLC lifted its stake in Eli Lilly and by 16.1% during the 3rd quarter. Janus Henderson Group PLC now owns 10,857,193 shares of the company’s stock valued at $928,719,000 after acquiring an additional 1,503,918 shares during the period. Dodge & Cox lifted its stake in Eli Lilly and by 22,094.9% during the 2nd quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock valued at $493,138,000 after acquiring an additional 5,964,955 shares during the period. Finally, Renaissance Technologies LLC lifted its stake in shares of Eli Lilly and by 91.1% in the 2nd quarter. Renaissance Technologies LLC now owns 5,694,905 shares of the company’s stock valued at $468,691,000 after purchasing an additional 2,714,505 shares during the period. 76.31% of the stock is currently owned by institutional investors and hedge funds.
Shares of Eli Lilly and Co (LLY) opened at $86.86 on Friday. Eli Lilly and Co has a 1-year low of $74.00 and a 1-year high of $89.09. The stock has a market cap of $95,120.00, a price-to-earnings ratio of 41.36, a PEG ratio of 1.62 and a beta of 0.35. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66.
Eli Lilly and (NYSE:LLY) last released its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The business had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. During the same quarter in the prior year, the firm earned $0.88 earnings per share. The company’s revenue for the quarter was up 9.0% compared to the same quarter last year. equities research analysts forecast that Eli Lilly and Co will post 4.22 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be issued a $0.5625 dividend. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.59%. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s dividend payout ratio is currently 99.05%.
In related news, SVP Susan Mahony sold 36,585 shares of the company’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $86.18, for a total value of $3,152,895.30. Following the completion of the sale, the senior vice president now owns 54,885 shares of the company’s stock, valued at $4,729,989.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the company’s stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $83.67, for a total transaction of $167,591.01. Following the completion of the sale, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The disclosure for this sale can be found here. Insiders sold 251,088 shares of company stock valued at $22,041,236 in the last three months. 0.20% of the stock is currently owned by insiders.
Several research firms recently issued reports on LLY. BMO Capital Markets reiterated a “sell” rating and issued a $71.00 target price on shares of Eli Lilly and in a research note on Thursday, September 28th. Cowen reissued a “buy” rating and issued a $95.00 price target on shares of Eli Lilly and in a report on Wednesday, October 4th. Piper Jaffray Companies reissued a “buy” rating and issued a $105.00 price target on shares of Eli Lilly and in a report on Friday, October 13th. Morgan Stanley set a $86.00 price target on shares of Eli Lilly and and gave the stock a “hold” rating in a report on Friday, October 6th. Finally, Goldman Sachs Group reissued a “buy” rating and issued a $95.00 price target (up previously from $92.00) on shares of Eli Lilly and in a report on Thursday, October 5th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and ten have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $92.14.
TRADEMARK VIOLATION NOTICE: “Eli Lilly and Co (LLY) Shares Bought by Indiana Trust & Investment Management CO” was first posted by Transcript Daily and is the property of of Transcript Daily. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://transcriptdaily.com/2018/01/12/eli-lilly-and-co-lly-shares-bought-by-indiana-trust-investment-management-co.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.